Viking Therapeutics, Inc. (VKTX) debt
What Viking Therapeutics owes, when it comes due, and what it costs to carry, from the balances and cash flows the company reports to the U.S. Securities and Exchange Commission.
At a glance
| Metric | Sep 2026 | Year earlier | Change |
|---|---|---|---|
| Total debt | $251M | — | — |
| Long-term debt | $251M | — | — |
| Cash and equivalents | $678M | — | — |
| Net cash | $427M | — | — |
Total debt is the sum of the debt lines the company reports at that date (long-term, current and short-term borrowings), not a figure the company reports as a total.
Debt over time
| Balance date | Total debt | Due within a year | Long-term debt | Cash |
|---|---|---|---|---|
| Sep 2026 | $251M† | — | $251M | $678M |
| Dec 2025 | $0† | — | $0 | $166M |
| Mar 2018 | — | $4M | — | $36M |
| Dec 2017 | — | $3M | — | $9M |
| Sep 2017 | — | $3M | — | $3M |
| Jun 2017 | — | $3M | — | $3M |
| Mar 2017 | $4M† | — | $4M | $4M |
| Dec 2016 | — | $3M | — | $3M |
| Sep 2016 | — | $3M | — | $3M |
| Jun 2016 | — | $2M | — | $5M |
| Mar 2016 | $3M† | — | $3M | $4M |
| Dec 2015 | $2M† | — | $2M | $768,550 |
† Sum of the debt lines the company reports at that date, not a reported total.
Interest cost and borrowing
| Fiscal year | Interest expense | Borrowed | Repaid | Convertible notes repaid |
|---|---|---|---|---|
| FY Dec 2018 | — | — | — | $4M |
| FY Dec 2017 | — | — | — | $77,000 |
| FY Dec 2016 | — | — | — | $94,861 |
About these figures
These are the balances Viking Therapeutics reports in its SEC filings as of each balance-sheet date, and the interest, borrowing and repayments it reports for each period. This page does not show market prices or yields of the company's bonds. "Long-term debt" is the line as the company tags it in its filings and may or may not include the portion due within a year.
All figures from company filings with the SEC.